Want to join the conversation?
$LLY said it decided to discontinue developing basal insulin peglispro, a potential treatment for type 1 & 2 diabetes in order to focus R&D efforts on other assets in its portfolio. This decision will result in a 4Q15 charge to $LLY's GAAP & non-GAAP R&D expense of about $0.03/share (after-tax). $LLY's previously issued guidance remains unchanged.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!